AstraZeneca Places US$240 M Bet on Moderna Therapeutics’ mRNA Technology
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 8 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1918 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
AstraZeneca has signed an option-based deal with start-up Moderna Therapeutics to discover, develop and commercialise up to 40 messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018